Limited (LON:HCM – Get Free Report) crossed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of GBX 274.45 ($3.38) and traded as low as GBX 232.04 ...

Hutchmed, a biopharmaceutical company controlled by Hong Kong’s wealthiest person Li Ka-shing, is divesting a 45% stake in a cardiovascular joint venture for about ...

HUTCHMED (China) Limited (NASDAQ:HCM – Get Free Report)’s stock price gapped up before the market opened on Friday . The stock had previously closed at $13.32, but opened at $13.99.

Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) today announces that the supplemental New Drug Application for ORPATHYS ® (savolitinib) has been granted approval by the China National Medical ...

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Jan. 01, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) announces that it has entered into two ...

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Jan. 14, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) today announces that the supplemental New ...

HUTCHMED continues to deliver on its strategy outlined in November 2022 to create value, prioritize its portfolio and bring innovative medicines to patients globally — — Divestment proceeds ...

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Jan. 01, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) announces that it has entered into two agreements to ...